CTNI-41. RESULTS OF A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE 2 STUDY OF THE RADIOPHARMACEUTICAL [177LU]LU-DOTA-TATE IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA
Sylvia C. Kurz(Center for Neuro-Oncology), Erik P. Sulman(NYU Langone Health), Elçin Zan(Cornell University), Marissa Barbaro(NYU Langone Health), Kent Friedman(New York University), David Zagzag(NYU Langone Health), Glen Stevens(Cleveland Clinic), Douglas Kondziolka(Neurological Surgery), John G. Golfinos(NYU Langone Health), Alejandro Torres-Trejo(Cleveland Clinic), Mina Lobbous(Cleveland Clinic), Andrew Dhawan(Cleveland Clinic), Mark G. Malkin(Cleveland Clinic), Alexandra Miller(Memorial Sloan Kettering Cancer Center), Matija Snuderl, Joshua S. Silverman(NYU Langone Health), Christine Cordova(Cleveland Clinic), Timothy M. Shepherd(NYU Langone Health), Andrea B. Troxel(Andover Eye Associates)
Cited by 1
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
|New England Journal of Medicine|2020|1.1k
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
|Nature Medicine|2018|927